Purchase this article with an account.
H.P. Sandoval, L.E. Fernandez de Castro, D.T. Vroman, K.D. Solomon; Comparison of 04% Ketorolac Tromethamine Ophthalmic Solution vs 05% Ketorolac Tromethamine Ophthalmic Solution to Prevent Inflammation After Phacoemulsification and Intraocular Lens Implantation: A Prospective, Randomized, Double–Masked, Clinical Trial . Invest. Ophthalmol. Vis. Sci. 2005;46(13):796.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To compare the safety and efficacy of 0.4% ketorolac tromethamine ophthalmic solution (Acular LS) vs. 0.5% ketorolac tromethamine ophthalmic solution (Acular) to prevent inflammation after cataract surgery. Patients and Methods: Prospective, randomized, double–masked, clinical trial that included a total of 40 patients undergoing phacoemulsification and IOL implantation. Patients were randomized to either ketorolac tromethamine 0.4% (n=20) or 0.5% (n=20) ophthalmic solution. Drops were used QID for 1 week and BID for 3 weeks and discontinued. IOP, laser cell/flare meter, anterior chamber cells count using SLE, and severity of ocular symptoms were evaluated preoperatively, and at 1, 7 and 30 days postoperatively. Statistical analysis was performed using a 2–sided paired t–test. A P < .05 was considered statistically significant. Results: Preoperatively, no significant differences were found among the 2 groups (P > .05). Statistically significant differences were found at one week in anterior chamber cells and flare between the two groups. Patient complained of less foreign body sensation with 0.4% ketorolac tromethamine. The rest of the evaluated parameters showed no differences at any time point. Conclusions: Both medications were effective in preventing inflammation; however 0.4% ketorolac tromethamine.5 % was associated with less anterior chamber cells, flare and ocular symptoms.
This PDF is available to Subscribers Only